Literature DB >> 10617240

Lung transplantation for patients with end-stage Sauropus androgynus-induced bronchiolitis obliterans (SABO) syndrome.

S P Luh1, Y C Lee, Y L Chang, H D Wu, S H Kuo, S H Chu.   

Abstract

Sauropus androgymus (SA), a vegetable of the Euphorbiaceae family, is a common food source in Malaysia. In Taiwan, over 30 patients have developed progressive respiratory failure after consuming the extract from raw SA leaves as a means of losing weight. Symptoms consistent with a severe obstructive ventilatory defect progressed, despite cessation of SA intake and treatment with bronchodilators, corticosteroids, cytotoxic agents and plasmaphresis. Five patients with end-stage Sauropus androgynus-induced bronchiolitis obliterans (SABO) syndrome underwent lung transplantation. There was no early mortality. One patient died of post-transplant lymphoproliferative disorder and another patient died of bronchial stenosis with infection, 5 and 3.5 months, respectively, post-transplantation. The remaining 3 patients have been followed from 29 to 34 months, with improved general condition and pulmonary function. Perfusion/ventilation scans revealed that these improvements were exclusively attributed to the functional grafts. We believe that lung transplantation is the only effective modality of treatment for patients with end-stage SABO syndrome.

Entities:  

Mesh:

Year:  1999        PMID: 10617240     DOI: 10.1034/j.1399-0012.1999.130610.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  2 in total

Review 1.  Bronchiolitis obliterans.

Authors:  Petey Laohaburanakit; Andrew Chan; Roblee P Allen
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

Review 2.  Sauropus androgynus (L.) Merr. Induced Bronchiolitis Obliterans: From Botanical Studies to Toxicology.

Authors:  Hamidun Bunawan; Siti Noraini Bunawan; Syarul Nataqain Baharum; Normah Mohd Noor
Journal:  Evid Based Complement Alternat Med       Date:  2015-08-27       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.